Barclays Maintains Overweight Rating on Indivior
Barclays maintained its Overweight rating on Indivior Pharmaceuticals.
Related stories
Donegal Group Reports Quarterly Results for Period Ended September 30
M impact | EQUITY | Oct 29, 2026, 02:07 PM UTC
InterDigital rises after Q3 results beat and upbeat profit forecast
InterDigital shares rose after the company reported Q3 results that beat expectations and issued an upbeat profit forecast.
M impact | EQUITY | Oct 29, 2026, 02:07 PM UTC
Adidas Publishes Q3 2026 Results Presentation
Adidas published its Q3 2026 results presentation.
M impact | EQUITY | Oct 29, 2026, 02:07 PM UTC
Sinopec Q3 Profit Rises to RMB13.361 Billion
China Petroleum And Chemical Corp. reported third-quarter earnings of RMB13.361 billion, or RMB0.111 per share, versus RMB8.501 billion, or RMB0.070 per share, a year earlier.
M impact | EQUITY | Oct 29, 2026, 02:07 PM UTC
Xiamen ITG Q3 Net Profit Rises 51.33% Year Over Year
M impact | EQUITY | Oct 29, 2026, 02:06 PM UTC
Resolute Says Syama Mine Stabilised, Output Expected to Rebound
Resolute Mining executives said its flagship Syama gold mine in Mali has largely stabilised after months of operational disruptions, with production expected to rebound sharply in
M impact | EQUITY | Oct 29, 2026, 02:05 PM UTC